Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.

[1]  B. Besse,et al.  Narrative review of immunotherapy in thymic malignancies , 2021, Translational lung cancer research.

[2]  U. Ahmad.  The eighth edition TNM stage classification for thymic tumors: What do I need to know? , 2020, The Journal of thoracic and cardiovascular surgery.

[3]  Tomoaki Yamada,et al.  Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. , 2020, The Lancet. Oncology.

[4]  G. Giaccone,et al.  The IASLC Thymic Tumors Staging Project. The Impact of the 8th Edition of the UICC/AJCC TNM Stage Classification of Thymic Tumors: Results of a Survey. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  V. Torri,et al.  Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). , 2018, Cancer treatment reviews.

[6]  N. Mulet-Margalef,et al.  Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives , 2016, OncoTargets and therapy.

[7]  N. Girard,et al.  Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. , 2016, Lung cancer.

[8]  C. Porta,et al.  Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Ahn,et al.  RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  P. Meltzer,et al.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. , 2015, The Lancet. Oncology.

[11]  E. Rendina,et al.  Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study. , 2014, Lung cancer.

[12]  J. Burke,et al.  Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Barrios,et al.  Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma , 2012, Cancer.

[14]  J. Blay,et al.  Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  G. Demetri,et al.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.

[16]  U. Harmenberg,et al.  Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Blay,et al.  Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. , 2009, European journal of cancer.

[18]  C. Divino,et al.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.

[19]  B. Rini,et al.  Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients , 2008, Clinical Cancer Research.

[20]  M. Raica,et al.  Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. , 2008, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[21]  J. Blay,et al.  Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST , 2007 .

[22]  Y. Matsuzaki,et al.  Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. , 2002, The Journal of thoracic and cardiovascular surgery.